AKTS
Aktis Oncology, Inc.
$28.69
+1.11 (+4.02%)
At close · Jul 8
Market Cap
$1.59B
Shares
55,277,447
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$28.69
Open$27.00
Day$26.53–29.01
52W$14.72–34.19
Avg vol 30d448K
Short int2.9M · 5.3% float · 11.6d
Short vol84%
Last earningsMay 11, 2026
DataJan 2026–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+30%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+51%
trailing
6-month return
+34%
trailing
Relative strength
+27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
3 of 68 funds reported for Jun 30 · net +40.2K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.27% of float · ▲ +9.3% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
68 holders — 13F breadth
Squeeze score
84
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+30%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
3 of 68 funds reported for Jun 30 · net +40.2K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.27% of float · ▲ +9.3% MoM · 11.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
68 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $15
Now $29 · 72%
52-wk high $34
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKTS
this stock
Aktis Oncology, Inc.
|
$1.59B | — | — | — | 5.3% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKTS | -11.0% | +51.2% | +34.4% | -11.0% | — |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -11.9% | +49.9% | +26.8% | -11.1% | — |